NMPA Streamlines Class II Device Review Pathway; CMDE Releases New Technical Guidance
China's Center for Medical Device Evaluation (CMDE) released updated technical guidance for Class II medical device registration, introducing a streamlined documentation pathway expected to reduce average review timelines by 20-30%.
01Key Changes in Review Pathway
The updated guidance consolidates previously separate submission documents into a unified dossier format. Manufacturers can now submit clinical evaluation reports based on literature review alone for well-established predicate device categories, eliminating the mandatory in-country clinical trial requirement that previously added 6-12 months to typical Class II timelines. The new pathway applies to 47 product categories including home-use diagnostic devices, rehabilitation equipment, and conventional therapeutic devices.
02Impact on Foreign Manufacturers
Overseas manufacturers with existing CE mark or FDA 510(k) clearance will benefit most, as the guidance explicitly recognizes these regulatory pathways as acceptable predicate evidence. This effectively lowers the entry barrier for European and American medical device companies seeking China market access. Industry analysts estimate the changes could accelerate time-to-market by 4-8 months for qualifying products.
03Okeyplus Readiness
Okeyplus regulatory team has completed internal training on the new guidance. Our updated service workflow integrates the streamlined pathway for all qualifying Class II registrations, enabling clients to leverage the accelerated timeline immediately. Contact us for a free assessment of how the new guidance affects your specific product category.
Want to know how these changes affect your product?
Our regulatory team offers a free assessment with concrete impact analysis within 5 business days.
Free Consultation